In recent years, numerous clinical studies have demonstrated the effectiveness of PCSK9 inhibitors in significantly reducing cardiovascular and cerebrovascular disease by markedly lowering LDL-C levels. Here, PCSK9 is linked to cerebrovascular disorder.